Pages that link to "Q34341887"
Jump to navigation
Jump to search
The following pages link to Maturing antibody-drug conjugate pipeline hits 30. (Q34341887):
Displaying 50 items.
- Development of polymeric micelles for targeting intractable cancers (Q26749611) (← links)
- Antibody-drug conjugates--an emerging class of cancer treatment (Q26770312) (← links)
- Capturing Biological Activity in Natural Product Fragments by Chemical Synthesis (Q26772873) (← links)
- Modulation of APC Function and Anti-Tumor Immunity by Anti-Cancer Drugs (Q26781522) (← links)
- Antibody-drug conjugates as novel anti-cancer chemotherapeutics (Q26800175) (← links)
- Comparative clinical pharmacokinetics of antibody-drug conjugates in first-in-human Phase 1 studies (Q26830923) (← links)
- An overview of clinical and commercial impact of drug delivery systems (Q27007143) (← links)
- Antibody Drug Conjugates: Preclinical Considerations (Q27022321) (← links)
- Challenges and advances in the assessment of the disposition of antibody-drug conjugates (Q28085074) (← links)
- Sortase Enzyme-Mediated Generation of Site-Specifically Conjugated Antibody Drug Conjugates with High In Vitro and In Vivo Potency (Q28546010) (← links)
- Development and Evaluation of a Fluorescent Antibody-Drug Conjugate for Molecular Imaging and Targeted Therapy of Pancreatic Cancer (Q28552050) (← links)
- Antibody Therapies in Cancer (Q31104000) (← links)
- A priori prediction of tumor payload concentrations: preclinical case study with an auristatin-based anti-5T4 antibody-drug conjugate (Q33574139) (← links)
- Enabling the controlled assembly of antibody conjugates with a loading of two modules without antibody engineering (Q33587970) (← links)
- Immunohistochemical evaluation of epithelial ovarian carcinomas identifies three different expression patterns of the MX35 antigen, NaPi2b (Q33629621) (← links)
- State-of-the-art in design rules for drug delivery platforms: lessons learned from FDA-approved nanomedicines (Q34045119) (← links)
- Synthetic aptamer-polymer hybrid constructs for programmed drug delivery into specific target cells (Q34408096) (← links)
- Aldehyde tag coupled with HIPS chemistry enables the production of ADCs conjugated site-specifically to different antibody regions with distinct in vivo efficacy and PK outcomes (Q34434128) (← links)
- Organocatalysts of oxidative protein folding inspired by protein disulfide isomerase (Q35285491) (← links)
- α-Enolase-binding peptide enhances drug delivery efficiency and therapeutic efficacy against colorectal cancer (Q35652276) (← links)
- Tumor radiosensitization by monomethyl auristatin E: mechanism of action and targeted delivery (Q35691410) (← links)
- A novel antibody-drug conjugate targeting SAIL for the treatment of hematologic malignancies (Q35764587) (← links)
- Building better monoclonal antibody-based therapeutics. (Q35817552) (← links)
- Antibody Drug Conjugates: Nonclinical Safety Considerations (Q35967917) (← links)
- High throughput cytotoxicity screening of anti-HER2 immunotoxins conjugated with antibody fragments from phage-displayed synthetic antibody libraries (Q36109883) (← links)
- Antibody Therapeutics in Oncology (Q36791878) (← links)
- An anti-HER2 antibody conjugated with monomethyl auristatin E is highly effective in HER2-positive human gastric cancer (Q37013285) (← links)
- Anti-tubulin drugs conjugated to anti-ErbB antibodies selectively radiosensitize (Q37329842) (← links)
- Therapeutic targets and new directions for antibodies developed for ovarian cancer. (Q37397674) (← links)
- Design and In Vivo Characterization of Immunoconjugates Targeting HIV gp160. (Q37593171) (← links)
- Potential of antibody-drug conjugates and novel therapeutics in breast cancer management. (Q37671599) (← links)
- Amrubicin: potential in combination with cisplatin or carboplatin to treat small-cell lung cancer (Q38129050) (← links)
- Industrial natural product chemistry for drug discovery and development. (Q38154186) (← links)
- Nanomedicines for cancer therapy: state-of-the-art and limitations to pre-clinical studies that hinder future developments. (Q38247299) (← links)
- Natural product and natural product derived drugs in clinical trials. (Q38247457) (← links)
- Preclinical Pharmacokinetic Considerations for the Development of Antibody Drug Conjugates (Q38275051) (← links)
- New horizons in therapeutic antibody discovery: opportunities and challenges versus small-molecule therapeutics (Q38289992) (← links)
- Application of Pharmacokinetic-Pharmacodynamic Modeling and Simulation for Antibody-Drug Conjugate Development (Q38350045) (← links)
- The development of therapeutic monoclonal antibodies: overview of the nonclinical safety assessment (Q38355263) (← links)
- Stable and Potent Selenomab-Drug Conjugates. (Q38432502) (← links)
- Antibody Drug Conjugates: Application of Quantitative Pharmacology in Modality Design and Target Selection (Q38453769) (← links)
- Developments and recent advancements in the field of endogenous amino acid selective bond forming reactions for bioconjugation. (Q38497871) (← links)
- An Introduction to the Regulatory and Nonclinical Aspects of the Nonclinical Development of Antibody Drug Conjugates (Q38537261) (← links)
- Bioanalytical approaches for characterizing catabolism of antibody-drug conjugates (Q38557519) (← links)
- Introducing Glycolinkers for the Functionalization of Cytotoxic Drugs and Applications in Antibody-Drug Conjugation Chemistry. (Q38736346) (← links)
- Translational Model-Based Strategy to Guide the Choice of Clinical Doses for Antibody-Drug Conjugates (Q38764062) (← links)
- Multiscale Modeling of Antibody-Drug Conjugates: Connecting Tissue and Cellular Distribution to Whole Animal Pharmacokinetics and Potential Implications for Efficacy. (Q38765188) (← links)
- Proteomic strategies in the search for novel pancreatic cancer biomarkers and drug targets: recent advances and clinical impact (Q38777938) (← links)
- Design and Validation of a Novel Generic Platform for the Production of Tetravalent IgG1-like Bispecific Antibodies. (Q38790644) (← links)
- Structurally Defined αMHC-II Nanobody-Drug Conjugates: A Therapeutic and Imaging System for B-Cell Lymphoma. (Q38797038) (← links)